Advancing regenerative
medicine Targeting Myocardial Infarction
& Heart Failure

HIGHLIGHTS

1 / 5

Pig Studies confirm that FSTL1 treatment results in 50% scar reduction and up to 75% recovery of heart function after myocardial infarction

HIGHLIGHTS

2 / 5

Awarded US patent covering pharmaceutical compositions of FSTL1

HIGHLIGHTS

3 / 5

Awarded NIH SBIR Grant $4.2 M (R&D Diabetic population)

HIGHLIGHTS

4 / 5

Executed collaborative agreement with Phosphorex to develop Q-Beads, a formulation of FSTL1 for subcutaneous delivery

HIGHLIGHTS

5 / 5

Regencor appoints Nodes as exclusive advisors

Myocardial Regeneration
The ultimate goal of clinical cardiology

Regencor's team envisions a future where myocardial infarctions no longer impose incurable & life threatening tissue damage or progression to heart failure

Subcutaneous Sustained Delivery via Pump:
A true game-changer in heart disease therapy

Our recombinant protein, delivered subcutaneously, reverses the formation of scar tissue. Scar tissue is the most serious complication after a myocardial infarction as it weakens the heart and leads to progressive heart failure.

Learn more about OUR TECHNOLOGY